
Watchman FLX Noninferior to DOACs in AF, but With Important Caveats
CHAMPION-AF showed that left atrial appendage occlusion with the Watchman FLX was noninferior to direct oral anticoagulants for a three-year composite of cardiovascular death, stroke, and systemic embolism in AF patients eligible for anticoagulation, and it reduced clinically relevant nonprocedural bleeding. However, the trial had low event rates, a signal of more ischemic strokes in the device arm, and questions about periprocedural bleeding and applicability, which means LAAO should be considered as an option in shared decision-making rather than a universal substitute for NOACs. Longer-term data from ongoing trials will help clarify its role in high-risk AF.


